Glucocorticoid Remediable Aldosteronism (GRA), also known as familial hyperaldosteronim type I (FH-I) is a form of inherited hypertension, transmitted as an autosomal dominant trait. The syndrome is characterised by high levels of aldosterone, suppressed plasma renin activity, high incidence of intracranial haemorrhage, and paradoxical sensitivity to glucocorticoid therapy. Not all patients develop sporadic hypokalaemia, and are often normokalaemic.
The pathogenetic mechanism derives from an asymmetrical crossing-over with a nonreciprocal recombination between the 11b-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) genes. The resulting chimaeric gene has 5 0 regulatory elements of CYP11B1 fused to 3 0 coding sequences of CYP11B2. The preferential expression of this mutant form of CYP11B2 drives a transcription process under the control of ACTH instead of physiological angiotensin II stimulus. 1 Since 1992 the availability of genetic tests capable of detecting the hybrid gene has streamlined diagnosis and facilitated the screening, allowing the detection of family members with a variable phenotype, ranging from severe refractory hypertension to mild forms of hypertension or even normal blood pressure levels. [2] [3] [4] GRA is considered a relatively infrequent disease, accounting for about 0.5-1% of primary aldosteronism (PA). In recent years, however, with the wide diffusion of the aldosterone to renin ratio (ARR) as a screening test, the estimated prevalence of primary aldosteronism (PA) has risen from 1 to 10-30% of all forms of hypertension, allowing the detection of subjects clinically indistinguishable from patients with essential hypertension. Considering the large phenotypic variability found among genetically affected GRA patients, the actual prevalence of GRA among the hypertensive population from a primary care setting still needs to be established. Moreover, in parallel with the change in PA prevalence, it could be theoretically higher than previously thought.
Fardella et al 5 evaluated the prevalence of GRA in 305 hypertensive Chilean patients and 205 normotensive controls, finding two GRA positives among 29 hypertensives with PA and one GRA genetically positive among three normotensive individuals. This report suggested a relevant prevalence of GRA in hypertensive patients. On the other hand, programmes that screened 300 patients from a British hypertension unit and 117 unrelated hypertensive from Jamaica failed to identify a single individual who carried the GRA recombination. 6, 7 We previously performed a population-based study in order to evaluate the prevalence of hypertension associated with an elevated ARR in a sample of 1462 adults aged 35-74 years, randomly selected from the population register of the Bussolengo Health District (Northern Italy) and representative of the total population of the district, accounting of 124 991 subjects. Of 412 identified hypertensive patients, 287 subjects agreed to give blood ( Figure 1 ). An aldosterone to active renin ratio X32 pg/ml/ pg/ml was considered as the cutoff value, equivalent to an aldosterone to renin activity ratio of 50 ng/dl/ng/ml/h. An elevated ARR was observed in 32.4% of hypertensive patients. 8 Thus, at least from a theoretical point of view, a number of possible GRApositive individuals could be The aim of this study was to evaluate the prevalence of GRA among these 287 hypertensive patients from a primary care setting. A total of 10 DNA samples were not available for technical reasons. All subjects had given written informed consent for genetic testing.
In 277 subjects long PCR for the detection of the chimaeric 11b-hydroxylase/aldosterone synthase gene was performed using the method described by MacConnachie et al 9 with a few modifications. Briefly, two separate PCR reactions were performed, in order to amplify the normal gene and the chimaeric gene. In the first reaction, both the sense primer of the 5 0 untranslated region of the CYP11B2 (Xl-4: 5 0 -CAAGGCTCC CTCTCATCTCACGATAAGATA-3 0 ) and the antisense primer in exon 5 of the CYP11B2 sequences (Xl-2b: 5 0 -AGTGGAGTCCTCCAGCTGCCT CTCAACC-3 0 ) were used for detection of aldosterone synthase (4.0 kb fragment). In the second reaction, the sense primer of the 5'untranslated region of CYP11B1 (Xl-1b: 5 0 TCTACGCTCATGCACCCCCAAT GAGTCCCTG-3 0 ) was specific for 11b-hydroxylase and the antisense primer was the same as used in the first assay specific for aldosterone synthase, resulting in the amplification of a segment of the chimeric gene (3.9 kb fragment). Each PCR included 0.375 U of Extensor HiFidelity PCR Enzyme Mix (Abgene), a hot start at 941C for 5 min, 30 cycles at 941C for 20 s, 671C for 20 s, 721C for 3 min, and a final extension at 721 for 5 min. A chimaeric DNA control was added to each reaction.
No chimaeric gene was found in the sample of subjects studied, thus providing evidence that the prevalence of GRA among Northern Italy hypertensive population is very low. Our data are consistent with the findings of Mulatero et al 10 reporting similarly null data on 117 patients with PA from Hypertension Unit of the same geographic area.
In Table 1 are summarised the most important data on GRA screening.
We therefore conclude that, at least in Northern Italy, GRA is a rare disease at very low prevalence among the general hypertensive population, and genetic testing does not appear to be cost effective in the diagnostic work up of hypertensive patients from a primary care setting.
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